Afficher la notice abrégée

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial

dc.rights.licenseopenen_US
dc.contributor.authorHOGAN, J.
dc.contributor.authorPEREZ, A.
dc.contributor.authorSELLIER-LECLERC, A. L.
dc.contributor.authorVRILLON, I.
dc.contributor.authorBROUX, F.
dc.contributor.authorNOBILI, F.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
dc.contributor.authorBESSENAY, L.
dc.contributor.authorAUDARD, V.
dc.contributor.authorFAUDEUX, C.
dc.contributor.authorMORIN, D.
dc.contributor.authorPIETREMENT, C.
dc.contributor.authorTELLIER, S.
dc.contributor.authorDJEDDI, D.
dc.contributor.authorECKART, P.
dc.contributor.authorLAHOCHE, A.
dc.contributor.authorROUSSEY-KESLER, G.
dc.contributor.authorULINSKI, T.
dc.contributor.authorBOYER, O.
dc.contributor.authorPLAISIER, E.
dc.contributor.authorCLOAREC, S.
dc.contributor.authorJOLIVOT, A.
dc.contributor.authorGUIGONIS, V.
dc.contributor.authorGUILMIN-CREPON, S.
dc.contributor.authorBAUDOUIN, V.
dc.contributor.authorDOSSIER, C.
dc.contributor.authorDESCHÊNES, G.
dc.date.accessioned2021-02-23T15:39:14Z
dc.date.available2021-02-23T15:39:14Z
dc.date.issued2020
dc.identifier.issn2044-6055en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26334
dc.description.abstractEnIntroduction Guidelines for the treatment of steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking. Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming to provide long-term remission while minimising treatment side effects are needed. Several studies confirm that rituximab is effective in preventing early relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 2 years). This trial will assess the association of intravenous immunoglobulins (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether IVIg’s immunomodulatory properties can alter the course of the disease and reduce the use of immunosuppressive drugs and their side effects. Methods and analysis We conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, controlled, superiority trial to assess the safety and efficacy of a single infusion of rituximab followed by IVIg compared with rituximab alone in childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse within 24 months. Patients are allocated to receive either rituximab alone (375 mg/m²) or rituximab followed by IVIg, which includes an initial Ig dose of 2 g/kg, followed by 1.5 g/kg injections once a month for the following 5 months (maximum dose: 100 g). Ethics and dissemination The study has been approved by the ethics committee (Comité de Protection des Personnes) of Ouest I and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subjectLEHA
dc.title.enEfficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
dc.title.alternativeBMJ Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/bmjopen-2020-037306en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32967877en_US
bordeaux.journalBMJ Openen_US
bordeaux.pagee037306en_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue9en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03150315
hal.version1
hal.date.transferred2021-02-23T15:39:19Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMJ%20Open&rft.date=2020&rft.volume=10&rft.issue=9&rft.spage=e037306&rft.epage=e037306&rft.eissn=2044-6055&rft.issn=2044-6055&rft.au=HOGAN,%20J.&PEREZ,%20A.&SELLIER-LECLERC,%20A.%20L.&VRILLON,%20I.&BROUX,%20F.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPh_BMJO_2020_Hogan.pdf
Taille:
371.3Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
920octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée